Therapy Areas: Hereditary Disorders
Maxor signs limited distribution agreement for Orkambi and Kalydeco
19 May 2017 -

Maxor National Pharmacy Services LLC (Maxor) reported on Thursday that it has signed a specialty pharmacy network distribution agreement with Vertex Pharmaceuticals Inc for the latter's Orkambi and Kalydeco products with immediate effect.

Maxor Specialty, which is comprised of IV Solutions and Pharmaceutical Specialties (PSI), has now been included in Vertex Pharmaceuticals Inc's specialty pharmacy network.

The patients may now get access to Vertex's Orkambi and Kalydeco, two leading medications used in the treatment of certain types of Cystic Fibrosis (CF), through Maxor Specialty.

Established in 1926, Maxor is a leading pharmacy services platform that consists of three primary business segments: MaxorPlus, Maxor Specialty, IV Solutions and Pharmaceutical Specialties as well as Maxor Pharmacy Management and Consulting Services.

Login
Username:

Password:


Related Headlines

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera